Tetra Bio-Pharma Inc.
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of immunomodulator drugs. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; and REBORN for the treatment of breakthrough cancer pain. It also develops novel prescription drugs and treatments to relieve symptoms associated with advanced cancer pain, chronic pain, Acut… Read more
Tetra Bio-Pharma Inc. (TBPMQ) - Net Assets
Latest net assets as of August 2022: $-5.91 Million USD
Based on the latest financial reports, Tetra Bio-Pharma Inc. (TBPMQ) has net assets worth $-5.91 Million USD as of August 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.02 Million) and total liabilities ($8.93 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-5.91 Million |
| % of Total Assets | -195.68% |
| Annual Growth Rate | -89.93% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 45.26 |
Tetra Bio-Pharma Inc. - Net Assets Trend (2019–2021)
This chart illustrates how Tetra Bio-Pharma Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tetra Bio-Pharma Inc. (2019–2021)
The table below shows the annual net assets of Tetra Bio-Pharma Inc. from 2019 to 2021.
| Year | Net Assets | Change |
|---|---|---|
| 2021-11-30 | $249.33K | -98.90% |
| 2020-11-30 | $22.59 Million | -8.37% |
| 2019-11-30 | $24.65 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tetra Bio-Pharma Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7865122300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (November 2021)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $91.79 Million | 36815.84% |
| Other Components | $35.19 Million | 14114.26% |
| Total Equity | $249.33K | 100.00% |
Tetra Bio-Pharma Inc. Competitors by Market Cap
The table below lists competitors of Tetra Bio-Pharma Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VHABW
PINK:VHABW
|
$83.88K |
|
IQ-AI LTD. LS -01
F:5Y1
|
$83.93K |
|
Pioneer High Income Closed Fund
NYSE:PHT
|
$83.97K |
|
EVOLUTION MIN
MU:WE7
|
$83.98K |
|
Cemex SAB de CV
STU:CEXA
|
$83.74K |
|
Il-Yang Pharmaceutical Co. Ltd.
KQ:007570
|
$83.74K |
|
XPS Pensions Group PLC
LSE:XPS
|
$83.71K |
|
CI Com SA
SW:CIE
|
$83.71K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tetra Bio-Pharma Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2020 to 2021, total equity changed from 22,588,786 to 249,334, a change of -22,339,452 (-98.9%).
- Net loss of 52,175,046 reduced equity.
- New share issuances of 26,305,461 increased equity.
- Other factors increased equity by 3,530,133.
Equity Change Factors (2020 to 2021)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-52.18 Million | -20925.76% |
| Share Issuances | $26.31 Million | +10550.29% |
| Other Changes | $3.53 Million | +1415.82% |
| Total Change | $- | -98.90% |
Book Value vs Market Value Analysis
This analysis compares Tetra Bio-Pharma Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.32x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.32x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-11-30 | $0.12 | $0.00 | x |
| 2020-11-30 | $0.08 | $0.00 | x |
| 2021-11-30 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tetra Bio-Pharma Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -20925.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 30.29x
- Recent ROE (-20925.76%) is below the historical average (-7034.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -62.00% | 0.00% | 0.00x | 1.16x | $-17.75 Million |
| 2020 | -117.21% | 0.00% | 0.00x | 1.30x | $-28.74 Million |
| 2021 | -20925.76% | 0.00% | 0.00x | 30.29x | $-52.20 Million |
Industry Comparison
This section compares Tetra Bio-Pharma Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tetra Bio-Pharma Inc. (TBPMQ) | $-5.91 Million | -62.00% | N/A | $83.75K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |